老虎證券
Invest
Pricing
Rewards
Support
About
Quotes
TigerAI
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
基因編輯
416.60
-12.8295
-2.99%
漲家數：
- -
跌家數：
4
平家數：
- -
市盈率：
- -
高：
428.74
開：
428.74
低：
413.06
收：
429.43
成交量：
950.47萬
成交額：
1.75億
市值：
94.03億
流通市值：
88.21億
資料載入中...
總覽
新聞資訊
數據：ARK Invest 旗下多隻 ETF 同步買入 NTLA 與 Solana 質押 ETF，並減持 SLMT
链捕手
·
09/11
CRISPR療法可降低「壞膽固醇」和甘油三酯
格隆汇
·
09/09
BUZZ——美國股市動態-Sigma Lithium、Shake Shack、諾華
路透中文
·
09/08
FDA授予Intellia公司一款罕見病治療藥物快速通道資格，其股價隨之上漲
路透中文
·
09/08
FDA優先審評Intellia罕見腫脹病療法 盤前股價應聲上漲4.9%
美股速递
·
09/08
Intellia Therapeutics獲美國FDA受理Lonvo-Z生物製劑許可申請，並獲優先審評資格，PDUFA日期定為2027年3月10日
美股速递
·
09/08
Intellia Therapeutics宣佈FDA優先審查其遺傳性血管性水腫（HAE）治療藥物Lonvoguran Ziclumeran（Lonvo-Z）生物製品許可申請
美股速递
·
09/08
Beam Therapeutics在歐洲呼吸學會2026年大會上公布Beam-302治療α-1抗胰蛋白酶缺乏症1/2期臨床試驗最新數據
美股速递
·
09/08
Intellia Therapeutics：五年合作期內，經雙方協商一致，可額外獲得1億美元資金
美股速递
·
09/04
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BK4556/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK4556","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"基因編輯","latestPrice":416.5977,"timestamp":1789502399999,"preClose":429.42715,"halted":0,"volume":9504706,"delay":0,"changeRate":-0.029876,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":-12.829468,"latestTime":"09-15 16:00:00 EDT","open":428.73895,"high":428.73895,"low":413.05756,"amount":174701679.229381,"amplitude":0.036517,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789516800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.593355,"peRate":-9.349618,"turnoverRate":0.021733,"increases":0,"decrements":4,"flats":0,"marketCap":9402707456,"floatMarketCap":8821016544},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":428.73895,"amplitude":0.036517,"preClose":429.42715,"low":413.05756,"pbRate":"2.593355","latestPrice":416.5977,"volume":9504706,"delay":0,"open":428.73895,"prevYearClose":431.70972,"prevWeekClose":422.4369,"prevMonthClose":478.4385,"prevQuarterClose":517.3469,"fiveDayClose":456.8296,"twentyDayClose":450.6346,"sixtyDayClose":503.1746,"secType":"PLATE","market":"US","turnoverRate":0.021733,"peRate":-9.349618,"marketCap":9402707456,"floatMarketCap":8821016544,"timestamp":1789502399999,"nameCN":"基因編輯"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":0,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666251448","title":"數據：ARK Invest 旗下多隻 ETF 同步買入 NTLA 與 Solana 質押 ETF，並減持 SLMT","url":"https://stock-news.laohu8.com/highlight/detail?id=2666251448","media":"链捕手","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666251448?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 08:18","pubTimestamp":1789085926,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据 Ark Invest Tracker 监测，ARK Invest 于 2026 年 9 月 10 日对旗下多只 ETF 进行了以下调仓操作：买入方向：ARKK、ARKG 同步买入 Intellia Therapeutics（NTLA），合计买入 89,284 股，分别占各基金总仓位的 0.0149% 和 0.0041%；ARKW、ARKF 同步买入 3IQ Solana Staking ETF（SOLQ.U），合计买入 4,021 股，分别占各基金总仓位的 0.001% 和 0.0019%。卖出方向：ARKK、ARKW、ARKF 同步减持 Brera Holdings PLC（SLMT），合计卖出 4,156 股，占比均不超过 0.0003%。 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2289015","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLON","SSS","BSOL","SOLC","ARKK","QSOL","SOLM","SOL.USD.CC","LU1861558580.USD","BK4588","LU1861559042.SGD","SOLZ","BK4550","SARK","SOLT","BK4544","ARKX","BK4600","HSDT","VSOL","BK4585","BK4108","NTLA","ARKG","BK4535","GSOL","ARKF","TSOL","ARKQ","SOLX","SOEZ","ARKW","BK4556","BK4139","SLMT","SSK","SOL.USD.HKCC","BK4082","FDN","FSOL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666308786","title":"CRISPR療法可降低「壞膽固醇」和甘油三酯","url":"https://stock-news.laohu8.com/highlight/detail?id=2666308786","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666308786?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 07:20","pubTimestamp":1788909654,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4611","SYNB","BK4585","BK4556","BK4139","ARKG","CRSP","LU1861559042.SGD","BK4588","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665375206","title":"BUZZ——美國股市動態-Sigma Lithium、Shake Shack、諾華","url":"https://stock-news.laohu8.com/highlight/detail?id=2665375206","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665375206?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:58","pubTimestamp":1788875887,"startTime":"0","endTime":"0","summary":"BUZZ——美国股市动态-Sigma Lithium、Shake Shack、诺华工作区中用于查询单只股票行情的搜索字符串：STXBZ《今日展望》通讯：https://refini.tv/3LI4BU7《晨间新闻简报》：https://refini.tv/3dKUyB8路透9月8日-周二开盘时，华尔街主要股指涨跌不一，中东地区新一轮冲突推动油价升至7月下旬以来的最高水平，而市场正在等待本周晚些时候","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4S45014M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN","LU1548497426.USD","BK4566","IE00B66KJ199.SGD","LU0345769631.USD","BK4131","BE","LU1861559042.SGD","UPGR","BSX","IE00BBT3K403.USD","IONC","IONS","LU0868494617.USD","LU2264538146.SGD","PBE","LU2357125470.USD","BK4504","LU2357305700.SGD","LU0306806265.USD","LU0058720904.USD","LU0128526141.USD","FRNW","LU0138981039.USD","IE00BJT1NW94.SGD","LU1066053197.SGD","LU1093756168.USD","LU1366192091.USD","LU0320765992.SGD","LU2491050071.SGD","LU0070302665.USD","LU0187121727.USD","ICLN","IE000M9KFDE8.USD","BK4556","BK4179","BEG","LU0433182093.SGD","IE00B3T34201.USD","LU1023059063.AUD","SHAK","LU0456855351.SGD","BK4567","SMOG","LU0122379950.USD","BK4209","LU1989764748.USD","LU2491049909.HKD","XES","IE00BLSP4239.USD","EGGY","CTEC","LU1571399168.USD","LU1066051498.USD","LU2543165471.USD","BEC","BK4120","LU0321505439.SGD","LU0823414478.USD","LU1878469433.USD","BK4533","LU0320765489.SGD","PHVS","LU1291159041.SGD","LU1989764664.SGD","LU0476273544.USD","RGTX","LU2242649171.HKD","LU0306807586.USD","BK4121","LU0345769128.USD","LU0823414551.USD","LU0985489474.SGD","LU0225771236.USD","BK4141","LU1720051108.HKD","LU1057294990.SGD","OZEM","BK4588","IE00B7SZL793.SGD","IE0031619046.USD","LU2265009873.SGD","LU2242646821.SGD","WQTM","TBXU","BK4585","LU1989772840.SGD","04332","LU2294711713.HKD","BK4168","IE00B19Z3B42.SGD","LU0234572021.USD","IONQ","LU0957808578.USD","OIH","PJP","LU1894683348.USD","BK4599","CQTM","ROIV","LU1720051017.SGD","SRPT","LU2468319806.SGD","SG9999001176.SGD","LU1983299246.USD","BK4534","LU0077335932.USD","LU0211331839.USD","USNG","BK4102","ALV","IE0009354923.USD","PPH","LU0353189763.USD","CHRW","LU0823416689.USD","RGTU","LU0114720955.EUR","LU0444971666.USD","LU2362540622.SGD","QTUP","LU0011850046.USD","DYN","LU0029874061.USD","LU1791710582.SGD","LU0878866978.SGD","SGML","VTWG","RGTC","IBAT","LU0225283273.USD","LU2087625088.SGD","BK4602","IE00B19Z4B17.USD","BK4578","IOYY","WATS","SEI","LU1153585028.USD","LU2362541513.USD","LU2506952170.USD","BK4581","LU1061106388.HKD","LU2249611893.SGD","LU0170899867.USD","LU0048584097.USD","LU0353189680.USD","BIB","LU0266013472.USD","VCLN","UNFI","LU0882574055.USD","SGXZ57979304.SGD","LU0889565916.HKD","SG9999001440.SGD","LU0289739699.SGD","NTLA","IONL","HYDR","IE00BJJMRZ35.SGD","LU2098885051.SGD","BK4592","IBBQ","LU2491050154.USD","BK4541","SG9999002232.USD","BK4124","IE0009355771.USD","LU2506951958.HKD","BK4597","LU1989772923.USD","LU0238689110.USD","BK4082","LU0985481810.HKD","LU1883839398.USD","LU2506951792.HKD","LU2596442595.SGD","LU0068578508.USD","LU0225284248.USD","MEDX","IE00B4R5TH58.HKD","LU1064131342.USD","LU1791710400.SGD","BEZ","IE00BFTCPJ56.SGD","BK4591","BK4532","LU1804176565.USD","LU2362541273.HKD","RGTZ","LU0950375773.USD","LU1642822529.SGD","LU0432979614.USD","LU2324357040.USD","IE0002270589.USD","SG9999002224.SGD","LU2242652126.USD","BEX","IONX","LU0109394709.USD","LU0528227936.USD","LU2244417387.USD","BBH","IE00BLSP4452.SGD","SG9999003800.SGD","BK4139","LU1894683264.USD","GNOM","BK4568","ILMN","RGTI","BK4170","IE0002141913.USD","RGYY","LU1718418525.SGD","LU1989771016.USD","IBB","SG9999001176.USD","CNRG","LU2089984988.USD","LU0208291251.USD","LU2506951875.HKD","LU1489326972.SGD","ABM","BK4548","SG9999011175.SGD","LU0251132253.USD","LU1815336760.USD","BK4182","GNMX","LU2112291526.USD","LU0823417653.USD","LU1988902786.USD","BK4505","SIMS","LU0823417737.USD","BK4007","BK4535","NVS","LU0321505868.SGD","IE00B2B36J28.USD","IONZ","LU0444973449.USD","LU1093756325.SGD","LU1861558580.USD","SG9999013999.USD","PTH","SRPU","BK4550","IE00B19Z3581.USD","LU0267386448.USD","LU1303367103.USD","ZAP","PFE","IE0034235188.USD","BHVN","LU2506952097.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665558378","title":"FDA授予Intellia公司一款罕見病治療藥物快速通道資格，其股價隨之上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2665558378","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665558378?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:30","pubTimestamp":1788870629,"startTime":"0","endTime":"0","summary":"BUZZ-FDA授予Intellia公司一款罕见病治疗药物快速通道资格，其股价随之上涨9月8日-** Intellia Therapeutics（NTLA.O）股价在盘前交易中上涨6.4%，至13.55美元** 该公司表示，美国食品药品监督管理局（FDA）已受理其申请，寻求批准将lonvoguran ziclumeran（简称lonvo-z）作为遗传性血管性水肿（HAE）的实验性治疗药物，并授予其","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4S4500YY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","NTLA","LU1861558580.USD","BK4556","BK4588","BK4139","BK4535","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108544920","title":"FDA優先審評Intellia罕見腫脹病療法 盤前股價應聲上漲4.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1108544920","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108544920?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:18","pubTimestamp":1788869895,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已同意对Intellia Therapeutics公司一款治疗罕见肿胀疾病的药物进行快速通道审评。受此利好消息提振，该公司股价在盘前交易时段攀升4.9%。\n这一进展标志着Intellia Therapeutics在推进其创新疗法方面迈出了关键一步。获得FDA快速通道资格意味着该药物有望加速上市进程，为饱受罕见病困扰的患者带来新的治疗曙光。\n市场对这一消息反应积极，投资者普遍看好该疗法的商业化前景。分析人士指出，快速通道认定通常意味着监管机构认可该药物在解决未满足医疗需求方面具有显著潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTLA","BK4585","BK4556","BK4535","BK4139","LU1861559042.SGD","BK4588","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147894927","title":"Intellia Therapeutics獲美國FDA受理Lonvo-Z生物製劑許可申請，並獲優先審評資格，PDUFA日期定為2027年3月10日","url":"https://stock-news.laohu8.com/highlight/detail?id=1147894927","media":"美股速递","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147894927?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:06","pubTimestamp":1788869169,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics宣布，美国食品药品监督管理局（FDA）已正式受理其Lonvo-Z的生物制剂许可申请（BLA），同时授予该申请优先审评资格。根据相关规定，FDA的《处方药用户付费法案》（PDUFA）目标行动日期设定为2027年3月10日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1861559042.SGD","NTLA","BK4585","BK4139","LU1861558580.USD","BK4535","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172716505","title":"Intellia Therapeutics宣佈FDA優先審查其遺傳性血管性水腫（HAE）治療藥物Lonvoguran Ziclumeran（Lonvo-Z）生物製品許可申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1172716505","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172716505?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:01","pubTimestamp":1788868876,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics今日宣布，美国食品药品监督管理局已正式受理其针对遗传性血管性水肿的候选药物Lonvoguran Ziclumeran所提交的生物制品许可申请，并授予优先审评资格。Intellia Therapeutics公司高层在声明中强调，这一进展不仅对公司研发管线意义重大，更体现了其致力于运用基因编辑技术变革遗传性疾病治疗范式的坚定承诺。FDA的此项决定，也再次印证了Lonvo-Z在前期临床试验中所展现出的巨大潜力及其尚未被满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","BK4556","BK4588","LU1861558580.USD","NTLA","BK4535","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133255075","title":"Beam Therapeutics在歐洲呼吸學會2026年大會上公布Beam-302治療α-1抗胰蛋白酶缺乏症1/2期臨床試驗最新數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1133255075","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133255075?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 18:01","pubTimestamp":1788861674,"startTime":"0","endTime":"0","summary":"Beam Therapeutics于欧洲呼吸学会2026年大会上，公布了Beam-302在α-1抗胰蛋白酶缺乏症治疗领域1/2期临床试验的最新临床数据。在大会现场，Beam Therapeutics的研发团队详细阐述了受试者的生物标志物变化、肺功能指标改善趋势以及药物耐受性情况。公司方面表示，这些更新数据进一步验证了Beam-302的潜在疾病修饰作用，并支持其后续临床开发路径的推进。业内分析人士指出，这一进展不仅关乎Beam药业自身管线价值的重估，也可能对AATD现有标准治疗格局构成远期挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BEAM","LU1861559042.SGD","BK4505","BK4535","BK4585","LU1861558580.USD","BK4556","BK4139","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174139552","title":"Intellia Therapeutics：五年合作期內，經雙方協商一致，可額外獲得1億美元資金","url":"https://stock-news.laohu8.com/highlight/detail?id=1174139552","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174139552?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 20:56","pubTimestamp":1788526590,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics今日宣布，在为期五年的合作期限内，若双方达成共识，公司将有权获取一笔额外的1亿美元资金。此项安排为公司的财务规划提供了更大的灵活性与战略空间。值得注意的是，这笔资金的释放并非自动生效，而是需要合作各方在具体条款上达成一致意见。通过这一机制，Intellia能够在保持稳健发展的同时，根据实际需求动态调整资金使用策略，从而更好地支持其研发管线布局与长期创新目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4535","NTLA","LU1861558580.USD","BK4139","BK4588","BK4556","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}]}}